Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Posts Increased Q1 Losses, Lower Revenues


NEW YORK (GenomeWeb) – Regulus Therapeutics last week posted its first-quarter financial results, reporting a sharp increase in its net loss on higher expenses.

The company's net loss in the three-month period ended March 31, 2014 arrived at $12.7 million, or $.30 per share, compared with $7.2 million, or $.20 a share, last year.

Revenues in the quarter slipped to $1.6 million from $3.2 million, while research and development spending jumped to $9.6 million from $6.9 million. Regulus attributed this increase to the initiation of a Phase I trial for its hepatitis C therapy RG-101, as well as continued work on preclinical candidates.

General and administrative costs, meanwhile, edged up to $2.7 million from $1.9 million.

At the end of the first quarter, Regulus had cash, cash equivalents, and short-term investments totaling $114.6 million.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.